Overview

Study to Evaluate Monotherapy Compared to Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

Status:
Recruiting

Trial end date:
2026-06-30

Target enrollment:

Participant gender:

Summary

This Randomized Phase 3 Open-label Study will Evaluate the Efficacy of Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined with AB154 in Front-Line, PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Arcus Biosciences, Inc.

Treatments:

Carboplatin
Paclitaxel
Pemetrexed